SecBot SecBot
8-K ·Filed Jun 16, 2026

ORGO

Organogenesis Holdings Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001193125-26-272710
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This filing contains only routine annual meeting results and a board re-election. No material changes to operations, strategy, or financial outlook. Monitor next quarterly earnings for business performance updates.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
ORGO ▼ -36.32% at T+60d
NEUTRAL call -36.32% · α vs SPY -39.47% · entry $2.34 → $1.49
Entry = T+0 close
Jun 16, 2026
via day close
T+1d
+4.27%
call +4.27% · α +3.49%
$2.44
settled 4mo ago
T+5d
+4.27%
call +4.27% · α +5.32%
$2.44
settled 4mo ago
T+20d
+14.10%
call +14.10% · α +12.79%
$2.67
settled 3mo ago
T+60d
-36.32%
call -36.32% · α -39.47%
$1.49
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Organogenesis Holdings Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on June 15, 2026. All nine director nominees were elected, the advisory say-on-pay proposal was approved, and the appointment of RSM US LLP as independent auditor was ratified. Additionally, the holders of Series A Convertible Preferred Stock re-elected Garrett Lustig to the board. This is a routine governance filing with no material financial or operational impact.

Key Facts

  • All nine director nominees were elected at the 2026 Annual Meeting.
  • Advisory say-on-pay proposal was approved with 72,516,011 votes for, 12,722,258 against, and 61,328 abstentions.
  • Ratification of RSM US LLP as independent auditor was approved with 128,421,160 votes for, 856,933 against, and 286,328 abstentions.
  • Garrett Lustig was re-elected to the board by Series A Convertible Preferred Stock holders via written consent.
  • Total shares present or represented by proxy: 129,564,421 shares of Class A common stock (including 38,470,359 shares issuable upon conversion of Series A Convertible Preferred Stock).

Financial Impact

No financial impact from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-272710
Document: 0001193125-26-272710-index-headers.html0001193125-26-272710
Document: 0001193125-26-272710-index.html0001193125-26-272710
Document: 0001193125-26-272710.txt0001193125-26-272710
3 reports for ORGO
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ORGO — sortable, filterable
TypeNow
Jul 27, 2026
13w ago
Press Release
BULLISH ★ 6/10
$2.53 $0.9913▼ −60.82%▼ −65.17%$0.9244 (−63.46%)
Jun 16, 2026
18w ago
8-K
NEUTRAL ★ 2/10
$2.34 $1.49▼ −36.32%▼ −39.47%$0.9244 (−60.50%)
Apr 6, 2026
29w ago
Press Release
NEUTRAL ★ 1/10
$2.24 $2.44▲ +8.93%▼ −4.54%$0.9244 (−58.73%)
Showing 3 of 3

US Market Status

Market Open — Closes in 4h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026